The US Food and Drug Administration has appointed George Francis Tidmarsh, MD, PhD, as director of the Center for Drug Evaluation and Research (CDER).

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with reduced type 2 diabetes mellitus (T2DM)-related dementia risk compared with metformin.

The FDA has accepted for review the second resubmitted NDA for reproxalap for the treatment of the signs and symptoms of dry eye disease.

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Peripheral neuropathy (PN) risk factors seem to explain a higher prevalence of the disease among non-Hispanic Black individuals, but not among Hispanic individuals.